nodes	percent_of_prediction	percent_of_DWPC	metapath
Nadolol—ABCB1—Ethinyl Estradiol—osteoporosis	0.0699	0.42	CbGbCtD
Nadolol—ABCB1—Conjugated Estrogens—osteoporosis	0.0513	0.309	CbGbCtD
Nadolol—ABCB1—Estradiol—osteoporosis	0.045	0.271	CbGbCtD
Nadolol—Chest pain—Raloxifene—osteoporosis	0.00181	0.00233	CcSEcCtD
Nadolol—Alopecia—Ethinyl Estradiol—osteoporosis	0.00181	0.00232	CcSEcCtD
Nadolol—Agranulocytosis—Zoledronate—osteoporosis	0.0018	0.00232	CcSEcCtD
Nadolol—Chest pain—Ibandronate—osteoporosis	0.00179	0.00231	CcSEcCtD
Nadolol—Oedema—Estropipate—osteoporosis	0.00179	0.00231	CcSEcCtD
Nadolol—Hypertension—Calcitriol—osteoporosis	0.00178	0.00229	CcSEcCtD
Nadolol—Constipation—Etidronic acid—osteoporosis	0.00177	0.00228	CcSEcCtD
Nadolol—Dry skin—Estradiol—osteoporosis	0.00177	0.00227	CcSEcCtD
Nadolol—Bradycardia—Zoledronate—osteoporosis	0.00176	0.00227	CcSEcCtD
Nadolol—Chest pain—Calcitriol—osteoporosis	0.00176	0.00226	CcSEcCtD
Nadolol—Dry mouth—Ibandronate—osteoporosis	0.00175	0.00226	CcSEcCtD
Nadolol—Dry mouth—Calcitriol—osteoporosis	0.00172	0.00221	CcSEcCtD
Nadolol—Flatulence—Risedronate—osteoporosis	0.00171	0.0022	CcSEcCtD
Nadolol—Shock—Raloxifene—osteoporosis	0.00171	0.0022	CcSEcCtD
Nadolol—Gastritis—Estradiol—osteoporosis	0.00171	0.0022	CcSEcCtD
Nadolol—Shock—Ibandronate—osteoporosis	0.00169	0.00218	CcSEcCtD
Nadolol—Hyperhidrosis—Raloxifene—osteoporosis	0.00168	0.00216	CcSEcCtD
Nadolol—Abdominal distension—Estradiol—osteoporosis	0.00168	0.00216	CcSEcCtD
Nadolol—Alopecia—Pamidronate—osteoporosis	0.00167	0.00215	CcSEcCtD
Nadolol—Hyperhidrosis—Ibandronate—osteoporosis	0.00166	0.00214	CcSEcCtD
Nadolol—Nausea—Ergocalciferol—osteoporosis	0.00166	0.00213	CcSEcCtD
Nadolol—Bronchospasm—Estradiol—osteoporosis	0.00164	0.00211	CcSEcCtD
Nadolol—Insomnia—Estropipate—osteoporosis	0.00162	0.00209	CcSEcCtD
Nadolol—Paraesthesia—Estropipate—osteoporosis	0.00161	0.00207	CcSEcCtD
Nadolol—Visual impairment—Conjugated Estrogens—osteoporosis	0.00161	0.00207	CcSEcCtD
Nadolol—Anorexia—Calcitriol—osteoporosis	0.0016	0.00206	CcSEcCtD
Nadolol—Abdominal discomfort—Estradiol—osteoporosis	0.0016	0.00206	CcSEcCtD
Nadolol—Dyspepsia—Estropipate—osteoporosis	0.00158	0.00203	CcSEcCtD
Nadolol—Insomnia—Raloxifene—osteoporosis	0.00157	0.00202	CcSEcCtD
Nadolol—Syncope—Risedronate—osteoporosis	0.00156	0.002	CcSEcCtD
Nadolol—Insomnia—Ibandronate—osteoporosis	0.00155	0.002	CcSEcCtD
Nadolol—Dyspepsia—Alendronate—osteoporosis	0.00155	0.002	CcSEcCtD
Nadolol—Cough—Ethinyl Estradiol—osteoporosis	0.00155	0.002	CcSEcCtD
Nadolol—Fatigue—Estropipate—osteoporosis	0.00155	0.00199	CcSEcCtD
Nadolol—Paraesthesia—Ibandronate—osteoporosis	0.00154	0.00199	CcSEcCtD
Nadolol—Pain—Estropipate—osteoporosis	0.00153	0.00197	CcSEcCtD
Nadolol—Constipation—Estropipate—osteoporosis	0.00153	0.00197	CcSEcCtD
Nadolol—Alopecia—Zoledronate—osteoporosis	0.00153	0.00197	CcSEcCtD
Nadolol—Dyspepsia—Raloxifene—osteoporosis	0.00153	0.00197	CcSEcCtD
Nadolol—Loss of consciousness—Risedronate—osteoporosis	0.00153	0.00196	CcSEcCtD
Nadolol—Insomnia—Calcitriol—osteoporosis	0.00152	0.00196	CcSEcCtD
Nadolol—Weight increased—Estradiol—osteoporosis	0.00152	0.00195	CcSEcCtD
Nadolol—Cough—Risedronate—osteoporosis	0.00151	0.00195	CcSEcCtD
Nadolol—Dyspepsia—Ibandronate—osteoporosis	0.00151	0.00195	CcSEcCtD
Nadolol—Pain—Alendronate—osteoporosis	0.00151	0.00194	CcSEcCtD
Nadolol—Constipation—Alendronate—osteoporosis	0.00151	0.00194	CcSEcCtD
Nadolol—Hypertension—Risedronate—osteoporosis	0.0015	0.00193	CcSEcCtD
Nadolol—Decreased appetite—Ibandronate—osteoporosis	0.00149	0.00192	CcSEcCtD
Nadolol—Pain—Raloxifene—osteoporosis	0.00148	0.00191	CcSEcCtD
Nadolol—Depression—Estradiol—osteoporosis	0.00148	0.00191	CcSEcCtD
Nadolol—Fatigue—Ibandronate—osteoporosis	0.00148	0.00191	CcSEcCtD
Nadolol—Syncope—Pamidronate—osteoporosis	0.00148	0.0019	CcSEcCtD
Nadolol—Chest pain—Risedronate—osteoporosis	0.00148	0.0019	CcSEcCtD
Nadolol—Alopecia—Conjugated Estrogens—osteoporosis	0.00147	0.0019	CcSEcCtD
Nadolol—Constipation—Ibandronate—osteoporosis	0.00147	0.00189	CcSEcCtD
Nadolol—Pain—Ibandronate—osteoporosis	0.00147	0.00189	CcSEcCtD
Nadolol—Pruritus—Etidronic acid—osteoporosis	0.00147	0.00189	CcSEcCtD
Nadolol—Decreased appetite—Calcitriol—osteoporosis	0.00146	0.00188	CcSEcCtD
Nadolol—Oedema—Ethinyl Estradiol—osteoporosis	0.00145	0.00187	CcSEcCtD
Nadolol—Loss of consciousness—Pamidronate—osteoporosis	0.00145	0.00187	CcSEcCtD
Nadolol—Dry mouth—Risedronate—osteoporosis	0.00145	0.00186	CcSEcCtD
Nadolol—Conjunctivitis—Estradiol—osteoporosis	0.00144	0.00186	CcSEcCtD
Nadolol—Cough—Pamidronate—osteoporosis	0.00144	0.00185	CcSEcCtD
Nadolol—Constipation—Calcitriol—osteoporosis	0.00144	0.00185	CcSEcCtD
Nadolol—Pain—Calcitriol—osteoporosis	0.00144	0.00185	CcSEcCtD
Nadolol—Flatulence—Conjugated Estrogens—osteoporosis	0.00143	0.00184	CcSEcCtD
Nadolol—Hypertension—Pamidronate—osteoporosis	0.00142	0.00183	CcSEcCtD
Nadolol—Vision blurred—Zoledronate—osteoporosis	0.00142	0.00183	CcSEcCtD
Nadolol—Diarrhoea—Etidronic acid—osteoporosis	0.00142	0.00182	CcSEcCtD
Nadolol—Body temperature increased—Estropipate—osteoporosis	0.00142	0.00182	CcSEcCtD
Nadolol—Body temperature increased—Alendronate—osteoporosis	0.0014	0.0018	CcSEcCtD
Nadolol—Shock—Risedronate—osteoporosis	0.00139	0.00179	CcSEcCtD
Nadolol—Body temperature increased—Raloxifene—osteoporosis	0.00137	0.00177	CcSEcCtD
Nadolol—Vision blurred—Conjugated Estrogens—osteoporosis	0.00137	0.00176	CcSEcCtD
Nadolol—Body temperature increased—Ibandronate—osteoporosis	0.00136	0.00175	CcSEcCtD
Nadolol—Syncope—Zoledronate—osteoporosis	0.00135	0.00174	CcSEcCtD
Nadolol—Oedema—Pamidronate—osteoporosis	0.00135	0.00173	CcSEcCtD
Nadolol—Body temperature increased—Calcitriol—osteoporosis	0.00133	0.00171	CcSEcCtD
Nadolol—Shock—Pamidronate—osteoporosis	0.00132	0.0017	CcSEcCtD
Nadolol—Loss of consciousness—Zoledronate—osteoporosis	0.00132	0.0017	CcSEcCtD
Nadolol—Vomiting—Etidronic acid—osteoporosis	0.00132	0.00169	CcSEcCtD
Nadolol—Cough—Zoledronate—osteoporosis	0.00132	0.00169	CcSEcCtD
Nadolol—Rash—Etidronic acid—osteoporosis	0.00131	0.00168	CcSEcCtD
Nadolol—Dermatitis—Etidronic acid—osteoporosis	0.00131	0.00168	CcSEcCtD
Nadolol—Hyperhidrosis—Pamidronate—osteoporosis	0.0013	0.00167	CcSEcCtD
Nadolol—Syncope—Conjugated Estrogens—osteoporosis	0.0013	0.00167	CcSEcCtD
Nadolol—Hypertension—Zoledronate—osteoporosis	0.0013	0.00167	CcSEcCtD
Nadolol—Asthenia—Estropipate—osteoporosis	0.00129	0.00165	CcSEcCtD
Nadolol—Visual impairment—Estradiol—osteoporosis	0.00129	0.00165	CcSEcCtD
Nadolol—Anorexia—Pamidronate—osteoporosis	0.00128	0.00165	CcSEcCtD
Nadolol—Chest pain—Zoledronate—osteoporosis	0.00128	0.00165	CcSEcCtD
Nadolol—Insomnia—Risedronate—osteoporosis	0.00128	0.00165	CcSEcCtD
Nadolol—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.00128	0.00164	CcSEcCtD
Nadolol—Paraesthesia—Risedronate—osteoporosis	0.00127	0.00164	CcSEcCtD
Nadolol—Pruritus—Estropipate—osteoporosis	0.00127	0.00163	CcSEcCtD
Nadolol—Asthenia—Alendronate—osteoporosis	0.00127	0.00163	CcSEcCtD
Nadolol—Cough—Conjugated Estrogens—osteoporosis	0.00127	0.00163	CcSEcCtD
Nadolol—Dyspnoea—Risedronate—osteoporosis	0.00126	0.00162	CcSEcCtD
Nadolol—Hypotension—Pamidronate—osteoporosis	0.00126	0.00162	CcSEcCtD
Nadolol—Dry mouth—Zoledronate—osteoporosis	0.00125	0.00161	CcSEcCtD
Nadolol—Fatigue—Ethinyl Estradiol—osteoporosis	0.00125	0.00161	CcSEcCtD
Nadolol—Pruritus—Alendronate—osteoporosis	0.00125	0.00161	CcSEcCtD
Nadolol—Dyspepsia—Risedronate—osteoporosis	0.00125	0.0016	CcSEcCtD
Nadolol—Tinnitus—Estradiol—osteoporosis	0.00124	0.0016	CcSEcCtD
Nadolol—Constipation—Ethinyl Estradiol—osteoporosis	0.00124	0.0016	CcSEcCtD
Nadolol—Chest pain—Conjugated Estrogens—osteoporosis	0.00124	0.00159	CcSEcCtD
Nadolol—Asthenia—Ibandronate—osteoporosis	0.00123	0.00159	CcSEcCtD
Nadolol—Nausea—Etidronic acid—osteoporosis	0.00123	0.00158	CcSEcCtD
Nadolol—Oedema—Zoledronate—osteoporosis	0.00123	0.00158	CcSEcCtD
Nadolol—Diarrhoea—Estropipate—osteoporosis	0.00123	0.00158	CcSEcCtD
Nadolol—Fatigue—Risedronate—osteoporosis	0.00122	0.00157	CcSEcCtD
Nadolol—Insomnia—Pamidronate—osteoporosis	0.00122	0.00157	CcSEcCtD
Nadolol—Pruritus—Ibandronate—osteoporosis	0.00122	0.00156	CcSEcCtD
Nadolol—Constipation—Risedronate—osteoporosis	0.00121	0.00156	CcSEcCtD
Nadolol—Pain—Risedronate—osteoporosis	0.00121	0.00156	CcSEcCtD
Nadolol—Shock—Zoledronate—osteoporosis	0.00121	0.00156	CcSEcCtD
Nadolol—Paraesthesia—Pamidronate—osteoporosis	0.00121	0.00156	CcSEcCtD
Nadolol—Diarrhoea—Alendronate—osteoporosis	0.00121	0.00155	CcSEcCtD
Nadolol—Asthenia—Calcitriol—osteoporosis	0.00121	0.00155	CcSEcCtD
Nadolol—Dyspnoea—Pamidronate—osteoporosis	0.0012	0.00154	CcSEcCtD
Nadolol—Pruritus—Calcitriol—osteoporosis	0.00119	0.00153	CcSEcCtD
Nadolol—Hyperhidrosis—Zoledronate—osteoporosis	0.00119	0.00153	CcSEcCtD
Nadolol—Diarrhoea—Raloxifene—osteoporosis	0.00119	0.00153	CcSEcCtD
Nadolol—Dyspepsia—Pamidronate—osteoporosis	0.00119	0.00152	CcSEcCtD
Nadolol—Dizziness—Estropipate—osteoporosis	0.00119	0.00152	CcSEcCtD
Nadolol—Oedema—Conjugated Estrogens—osteoporosis	0.00118	0.00152	CcSEcCtD
Nadolol—Alopecia—Estradiol—osteoporosis	0.00118	0.00152	CcSEcCtD
Nadolol—Diarrhoea—Ibandronate—osteoporosis	0.00118	0.00151	CcSEcCtD
Nadolol—Anorexia—Zoledronate—osteoporosis	0.00117	0.00151	CcSEcCtD
Nadolol—Decreased appetite—Pamidronate—osteoporosis	0.00117	0.00151	CcSEcCtD
Nadolol—Dizziness—Alendronate—osteoporosis	0.00117	0.0015	CcSEcCtD
Nadolol—Shock—Conjugated Estrogens—osteoporosis	0.00117	0.0015	CcSEcCtD
Nadolol—Fatigue—Pamidronate—osteoporosis	0.00116	0.00149	CcSEcCtD
Nadolol—Pain—Pamidronate—osteoporosis	0.00115	0.00148	CcSEcCtD
Nadolol—Constipation—Pamidronate—osteoporosis	0.00115	0.00148	CcSEcCtD
Nadolol—Diarrhoea—Calcitriol—osteoporosis	0.00115	0.00148	CcSEcCtD
Nadolol—Hypotension—Zoledronate—osteoporosis	0.00115	0.00148	CcSEcCtD
Nadolol—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.00115	0.00148	CcSEcCtD
Nadolol—Dizziness—Raloxifene—osteoporosis	0.00115	0.00148	CcSEcCtD
Nadolol—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.00114	0.00147	CcSEcCtD
Nadolol—Flatulence—Estradiol—osteoporosis	0.00114	0.00147	CcSEcCtD
Nadolol—Vomiting—Estropipate—osteoporosis	0.00114	0.00147	CcSEcCtD
Nadolol—Dizziness—Ibandronate—osteoporosis	0.00114	0.00146	CcSEcCtD
Nadolol—Rash—Estropipate—osteoporosis	0.00113	0.00145	CcSEcCtD
Nadolol—Dermatitis—Estropipate—osteoporosis	0.00113	0.00145	CcSEcCtD
Nadolol—Anorexia—Conjugated Estrogens—osteoporosis	0.00113	0.00145	CcSEcCtD
Nadolol—Vomiting—Alendronate—osteoporosis	0.00112	0.00144	CcSEcCtD
Nadolol—Body temperature increased—Risedronate—osteoporosis	0.00112	0.00144	CcSEcCtD
Nadolol—Rash—Alendronate—osteoporosis	0.00111	0.00143	CcSEcCtD
Nadolol—Insomnia—Zoledronate—osteoporosis	0.00111	0.00143	CcSEcCtD
Nadolol—Dermatitis—Alendronate—osteoporosis	0.00111	0.00143	CcSEcCtD
Nadolol—Hypotension—Conjugated Estrogens—osteoporosis	0.00111	0.00142	CcSEcCtD
Nadolol—Paraesthesia—Zoledronate—osteoporosis	0.0011	0.00142	CcSEcCtD
Nadolol—Vomiting—Raloxifene—osteoporosis	0.0011	0.00142	CcSEcCtD
Nadolol—Dyspnoea—Zoledronate—osteoporosis	0.0011	0.00141	CcSEcCtD
Nadolol—Rash—Raloxifene—osteoporosis	0.00109	0.00141	CcSEcCtD
Nadolol—Dermatitis—Raloxifene—osteoporosis	0.00109	0.00141	CcSEcCtD
Nadolol—Vomiting—Ibandronate—osteoporosis	0.00109	0.00141	CcSEcCtD
Nadolol—Rash—Ibandronate—osteoporosis	0.00108	0.00139	CcSEcCtD
Nadolol—Dermatitis—Ibandronate—osteoporosis	0.00108	0.00139	CcSEcCtD
Nadolol—Dyspepsia—Zoledronate—osteoporosis	0.00108	0.00139	CcSEcCtD
Nadolol—Insomnia—Conjugated Estrogens—osteoporosis	0.00107	0.00138	CcSEcCtD
Nadolol—Vomiting—Calcitriol—osteoporosis	0.00107	0.00138	CcSEcCtD
Nadolol—Decreased appetite—Zoledronate—osteoporosis	0.00107	0.00138	CcSEcCtD
Nadolol—Nausea—Estropipate—osteoporosis	0.00106	0.00137	CcSEcCtD
Nadolol—Body temperature increased—Pamidronate—osteoporosis	0.00106	0.00137	CcSEcCtD
Nadolol—Paraesthesia—Conjugated Estrogens—osteoporosis	0.00106	0.00137	CcSEcCtD
Nadolol—Rash—Calcitriol—osteoporosis	0.00106	0.00136	CcSEcCtD
Nadolol—Fatigue—Zoledronate—osteoporosis	0.00106	0.00136	CcSEcCtD
Nadolol—Dermatitis—Calcitriol—osteoporosis	0.00106	0.00136	CcSEcCtD
Nadolol—Dyspnoea—Conjugated Estrogens—osteoporosis	0.00106	0.00136	CcSEcCtD
Nadolol—Pain—Zoledronate—osteoporosis	0.00105	0.00135	CcSEcCtD
Nadolol—Constipation—Zoledronate—osteoporosis	0.00105	0.00135	CcSEcCtD
Nadolol—Nausea—Alendronate—osteoporosis	0.00105	0.00135	CcSEcCtD
Nadolol—Dyspepsia—Conjugated Estrogens—osteoporosis	0.00104	0.00134	CcSEcCtD
Nadolol—Asthenia—Ethinyl Estradiol—osteoporosis	0.00104	0.00134	CcSEcCtD
Nadolol—Syncope—Estradiol—osteoporosis	0.00104	0.00134	CcSEcCtD
Nadolol—Nausea—Raloxifene—osteoporosis	0.00103	0.00133	CcSEcCtD
Nadolol—Decreased appetite—Conjugated Estrogens—osteoporosis	0.00103	0.00132	CcSEcCtD
Nadolol—Pruritus—Ethinyl Estradiol—osteoporosis	0.00103	0.00132	CcSEcCtD
Nadolol—Fatigue—Conjugated Estrogens—osteoporosis	0.00102	0.00131	CcSEcCtD
Nadolol—Nausea—Ibandronate—osteoporosis	0.00102	0.00131	CcSEcCtD
Nadolol—Loss of consciousness—Estradiol—osteoporosis	0.00102	0.00131	CcSEcCtD
Nadolol—Asthenia—Risedronate—osteoporosis	0.00102	0.00131	CcSEcCtD
Nadolol—Cough—Estradiol—osteoporosis	0.00101	0.0013	CcSEcCtD
Nadolol—Constipation—Conjugated Estrogens—osteoporosis	0.00101	0.0013	CcSEcCtD
Nadolol—Pain—Conjugated Estrogens—osteoporosis	0.00101	0.0013	CcSEcCtD
Nadolol—Hypertension—Estradiol—osteoporosis	0.001	0.00129	CcSEcCtD
Nadolol—Pruritus—Risedronate—osteoporosis	0.001	0.00129	CcSEcCtD
Nadolol—Nausea—Calcitriol—osteoporosis	0.000999	0.00129	CcSEcCtD
Nadolol—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000994	0.00128	CcSEcCtD
Nadolol—Chest pain—Estradiol—osteoporosis	0.000989	0.00127	CcSEcCtD
Nadolol—Body temperature increased—Zoledronate—osteoporosis	0.000972	0.00125	CcSEcCtD
Nadolol—Diarrhoea—Risedronate—osteoporosis	0.000969	0.00125	CcSEcCtD
Nadolol—Dry mouth—Estradiol—osteoporosis	0.000967	0.00124	CcSEcCtD
Nadolol—Asthenia—Pamidronate—osteoporosis	0.000966	0.00124	CcSEcCtD
Nadolol—Dizziness—Ethinyl Estradiol—osteoporosis	0.000961	0.00124	CcSEcCtD
Nadolol—Pruritus—Pamidronate—osteoporosis	0.000953	0.00123	CcSEcCtD
Nadolol—Oedema—Estradiol—osteoporosis	0.000948	0.00122	CcSEcCtD
Nadolol—Dizziness—Risedronate—osteoporosis	0.000937	0.00121	CcSEcCtD
Nadolol—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000936	0.0012	CcSEcCtD
Nadolol—Shock—Estradiol—osteoporosis	0.000933	0.0012	CcSEcCtD
Nadolol—Vomiting—Ethinyl Estradiol—osteoporosis	0.000924	0.00119	CcSEcCtD
Nadolol—Diarrhoea—Pamidronate—osteoporosis	0.000921	0.00119	CcSEcCtD
Nadolol—Hyperhidrosis—Estradiol—osteoporosis	0.000916	0.00118	CcSEcCtD
Nadolol—Rash—Ethinyl Estradiol—osteoporosis	0.000916	0.00118	CcSEcCtD
Nadolol—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000915	0.00118	CcSEcCtD
Nadolol—Vomiting—Risedronate—osteoporosis	0.000901	0.00116	CcSEcCtD
Nadolol—Rash—Risedronate—osteoporosis	0.000893	0.00115	CcSEcCtD
Nadolol—Dermatitis—Risedronate—osteoporosis	0.000892	0.00115	CcSEcCtD
Nadolol—Dizziness—Pamidronate—osteoporosis	0.00089	0.00115	CcSEcCtD
Nadolol—Asthenia—Zoledronate—osteoporosis	0.000882	0.00114	CcSEcCtD
Nadolol—Pruritus—Zoledronate—osteoporosis	0.00087	0.00112	CcSEcCtD
Nadolol—Nausea—Ethinyl Estradiol—osteoporosis	0.000863	0.00111	CcSEcCtD
Nadolol—Insomnia—Estradiol—osteoporosis	0.000857	0.0011	CcSEcCtD
Nadolol—Vomiting—Pamidronate—osteoporosis	0.000856	0.0011	CcSEcCtD
Nadolol—Paraesthesia—Estradiol—osteoporosis	0.000851	0.00109	CcSEcCtD
Nadolol—Asthenia—Conjugated Estrogens—osteoporosis	0.00085	0.00109	CcSEcCtD
Nadolol—Rash—Pamidronate—osteoporosis	0.000849	0.00109	CcSEcCtD
Nadolol—Dermatitis—Pamidronate—osteoporosis	0.000848	0.00109	CcSEcCtD
Nadolol—Dyspnoea—Estradiol—osteoporosis	0.000845	0.00109	CcSEcCtD
Nadolol—Diarrhoea—Zoledronate—osteoporosis	0.000842	0.00108	CcSEcCtD
Nadolol—Nausea—Risedronate—osteoporosis	0.000841	0.00108	CcSEcCtD
Nadolol—Pruritus—Conjugated Estrogens—osteoporosis	0.000838	0.00108	CcSEcCtD
Nadolol—Dyspepsia—Estradiol—osteoporosis	0.000834	0.00107	CcSEcCtD
Nadolol—Decreased appetite—Estradiol—osteoporosis	0.000824	0.00106	CcSEcCtD
Nadolol—Fatigue—Estradiol—osteoporosis	0.000817	0.00105	CcSEcCtD
Nadolol—Dizziness—Zoledronate—osteoporosis	0.000813	0.00105	CcSEcCtD
Nadolol—Constipation—Estradiol—osteoporosis	0.000811	0.00104	CcSEcCtD
Nadolol—Pain—Estradiol—osteoporosis	0.000811	0.00104	CcSEcCtD
Nadolol—Diarrhoea—Conjugated Estrogens—osteoporosis	0.00081	0.00104	CcSEcCtD
Nadolol—Nausea—Pamidronate—osteoporosis	0.0008	0.00103	CcSEcCtD
Nadolol—Dizziness—Conjugated Estrogens—osteoporosis	0.000783	0.00101	CcSEcCtD
Nadolol—Vomiting—Zoledronate—osteoporosis	0.000782	0.00101	CcSEcCtD
Nadolol—Rash—Zoledronate—osteoporosis	0.000776	0.000998	CcSEcCtD
Nadolol—Dermatitis—Zoledronate—osteoporosis	0.000775	0.000997	CcSEcCtD
Nadolol—Vomiting—Conjugated Estrogens—osteoporosis	0.000753	0.000969	CcSEcCtD
Nadolol—Body temperature increased—Estradiol—osteoporosis	0.000749	0.000964	CcSEcCtD
Nadolol—Rash—Conjugated Estrogens—osteoporosis	0.000747	0.000961	CcSEcCtD
Nadolol—Dermatitis—Conjugated Estrogens—osteoporosis	0.000746	0.00096	CcSEcCtD
Nadolol—Nausea—Zoledronate—osteoporosis	0.000731	0.00094	CcSEcCtD
Nadolol—Nausea—Conjugated Estrogens—osteoporosis	0.000703	0.000905	CcSEcCtD
Nadolol—Asthenia—Estradiol—osteoporosis	0.00068	0.000875	CcSEcCtD
Nadolol—Pruritus—Estradiol—osteoporosis	0.000671	0.000863	CcSEcCtD
Nadolol—Diarrhoea—Estradiol—osteoporosis	0.000649	0.000834	CcSEcCtD
Nadolol—Dizziness—Estradiol—osteoporosis	0.000627	0.000806	CcSEcCtD
Nadolol—Vomiting—Estradiol—osteoporosis	0.000603	0.000775	CcSEcCtD
Nadolol—ADRB2—G alpha (s) signalling events—PTH—osteoporosis	0.000599	0.0106	CbGpPWpGaD
Nadolol—Rash—Estradiol—osteoporosis	0.000598	0.000769	CcSEcCtD
Nadolol—Dermatitis—Estradiol—osteoporosis	0.000597	0.000768	CcSEcCtD
Nadolol—Nausea—Estradiol—osteoporosis	0.000563	0.000724	CcSEcCtD
Nadolol—ADRB3—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	0.000559	0.0099	CbGpPWpGaD
Nadolol—ADRB3—G alpha (s) signalling events—ADCY5—osteoporosis	0.000535	0.00947	CbGpPWpGaD
Nadolol—ADRB1—G alpha (s) signalling events—PTHLH—osteoporosis	0.000507	0.00898	CbGpPWpGaD
Nadolol—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000497	0.0088	CbGpPWpGaD
Nadolol—ADRB2—G alpha (s) signalling events—PTHLH—osteoporosis	0.000496	0.00878	CbGpPWpGaD
Nadolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	0.000479	0.00848	CbGpPWpGaD
Nadolol—ADRB3—Calcium Regulation in the Cardiac Cell—ADCY5—osteoporosis	0.000462	0.00818	CbGpPWpGaD
Nadolol—ADRB1—G alpha (s) signalling events—CALCA—osteoporosis	0.000446	0.0079	CbGpPWpGaD
Nadolol—ADRB2—G alpha (s) signalling events—CALCA—osteoporosis	0.000437	0.00773	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CALCR—osteoporosis	0.000423	0.00749	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—PTH1R—osteoporosis	0.000423	0.00749	CbGpPWpGaD
Nadolol—ABCB1—HIF-1-alpha transcription factor network—ENO1—osteoporosis	0.000419	0.00741	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—PTH1R—osteoporosis	0.000414	0.00732	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CALCR—osteoporosis	0.000414	0.00732	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—PTH1R—osteoporosis	0.000403	0.00713	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—CALCR—osteoporosis	0.000403	0.00713	CbGpPWpGaD
Nadolol—ADRB3—G alpha (s) signalling events—POMC—osteoporosis	0.000394	0.00697	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—PTH—osteoporosis	0.000374	0.00663	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—PTH1R—osteoporosis	0.000366	0.00647	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CALCR—osteoporosis	0.000366	0.00647	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—CNR2—osteoporosis	0.000365	0.00646	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—WNT1—osteoporosis	0.000343	0.00607	CbGpPWpGaD
Nadolol—ADRB1—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	0.000332	0.00587	CbGpPWpGaD
Nadolol—ADRB2—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	0.000325	0.00575	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—MGLL—osteoporosis	0.00032	0.00566	CbGpPWpGaD
Nadolol—ADRB1—G alpha (s) signalling events—ADCY5—osteoporosis	0.000318	0.00562	CbGpPWpGaD
Nadolol—ADRB2—G alpha (s) signalling events—ADCY5—osteoporosis	0.000311	0.0055	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—PTHLH—osteoporosis	0.00031	0.00549	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—MGLL—osteoporosis	0.000291	0.00514	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	0.000284	0.00503	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	0.000278	0.00492	CbGpPWpGaD
Nadolol—ADRB1—Calcium Regulation in the Cardiac Cell—ADCY5—osteoporosis	0.000274	0.00485	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—CALCA—osteoporosis	0.000273	0.00483	CbGpPWpGaD
Nadolol—ADRB2—Calcium Regulation in the Cardiac Cell—ADCY5—osteoporosis	0.000268	0.00475	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CALCR—osteoporosis	0.000239	0.00423	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PTH1R—osteoporosis	0.000239	0.00423	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—SOST—osteoporosis	0.000239	0.00423	CbGpPWpGaD
Nadolol—ABCB1—HIF-1-alpha transcription factor network—LEP—osteoporosis	0.000234	0.00414	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CALCR—osteoporosis	0.000234	0.00414	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PTH1R—osteoporosis	0.000234	0.00414	CbGpPWpGaD
Nadolol—ADRB1—G alpha (s) signalling events—POMC—osteoporosis	0.000234	0.00413	CbGpPWpGaD
Nadolol—ADRB2—G alpha (s) signalling events—POMC—osteoporosis	0.000229	0.00404	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—PTH—osteoporosis	0.000222	0.00393	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	0.000221	0.00392	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—PTH—osteoporosis	0.000217	0.00385	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CALCR—osteoporosis	0.000217	0.00384	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PTH1R—osteoporosis	0.000217	0.00384	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CNR2—osteoporosis	0.000217	0.00383	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CALCR—osteoporosis	0.000216	0.00382	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PTH1R—osteoporosis	0.000216	0.00382	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PTH1R—osteoporosis	0.000212	0.00376	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CALCR—osteoporosis	0.000212	0.00376	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CNR2—osteoporosis	0.000212	0.00375	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—PTH—osteoporosis	0.000212	0.00374	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—CNR2—osteoporosis	0.000206	0.00365	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—WNT1—osteoporosis	0.000204	0.0036	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—WNT1—osteoporosis	0.000199	0.00352	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—PTH—osteoporosis	0.000192	0.0034	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—MGLL—osteoporosis	0.00019	0.00336	CbGpPWpGaD
Nadolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000188	0.00332	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CNR2—osteoporosis	0.000187	0.00331	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—MGLL—osteoporosis	0.000186	0.00329	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—PTHLH—osteoporosis	0.000184	0.00326	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—PTHLH—osteoporosis	0.00018	0.00319	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—WNT1—osteoporosis	0.000176	0.00312	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—PTHLH—osteoporosis	0.000175	0.0031	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—MGLL—osteoporosis	0.000172	0.00305	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MGLL—osteoporosis	0.000172	0.00304	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—MGLL—osteoporosis	0.000169	0.00299	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—LRP5—osteoporosis	0.000168	0.00296	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CALCA—osteoporosis	0.000162	0.00287	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—LRP6—osteoporosis	0.00016	0.00284	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—PTHLH—osteoporosis	0.000159	0.00282	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CALCA—osteoporosis	0.000159	0.00281	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	0.000157	0.00279	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—CALCA—osteoporosis	0.000154	0.00273	CbGpPWpGaD
Nadolol—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—osteoporosis	0.000148	0.00261	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—POMC—osteoporosis	0.000143	0.00253	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SOST—osteoporosis	0.000142	0.00251	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CALCA—osteoporosis	0.00014	0.00248	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SOST—osteoporosis	0.000139	0.00245	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—TLN1—osteoporosis	0.000135	0.00239	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—IL1B—osteoporosis	0.000129	0.00229	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PTH1R—osteoporosis	0.000128	0.00227	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CALCR—osteoporosis	0.000128	0.00227	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PTH—osteoporosis	0.000126	0.00222	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PTH1R—osteoporosis	0.000125	0.00222	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CALCR—osteoporosis	0.000125	0.00222	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—ANXA2—osteoporosis	0.000124	0.00219	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PTH—osteoporosis	0.000123	0.00217	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CNR2—osteoporosis	0.000122	0.00217	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CNR2—osteoporosis	0.00012	0.00212	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—P4HB—osteoporosis	0.000117	0.00206	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PTH—osteoporosis	0.000114	0.00202	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PTH—osteoporosis	0.000113	0.00201	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PTH—osteoporosis	0.000112	0.00197	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—RAP1A—osteoporosis	0.000112	0.00197	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000111	0.00197	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CNR2—osteoporosis	0.000111	0.00197	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CNR2—osteoporosis	0.000111	0.00196	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—ADCY5—osteoporosis	0.00011	0.00194	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000109	0.00193	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—NFATC1—osteoporosis	0.000109	0.00193	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CNR2—osteoporosis	0.000109	0.00192	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—DKK1—osteoporosis	0.000108	0.00191	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—WNT1—osteoporosis	0.000104	0.00185	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PTHLH—osteoporosis	0.000104	0.00184	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—WNT1—osteoporosis	0.000104	0.00184	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—WNT1—osteoporosis	0.000102	0.00181	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MGLL—osteoporosis	0.000102	0.0018	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PTHLH—osteoporosis	0.000102	0.0018	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—FGA—osteoporosis	0.000101	0.00179	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—TGFB1—osteoporosis	0.0001	0.00178	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—ADCY5—osteoporosis	9.97e-05	0.00176	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MGLL—osteoporosis	9.96e-05	0.00176	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—LRP5—osteoporosis	9.94e-05	0.00176	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—LRP5—osteoporosis	9.73e-05	0.00172	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	9.55e-05	0.00169	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—LRP6—osteoporosis	9.51e-05	0.00168	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PTHLH—osteoporosis	9.45e-05	0.00167	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PTHLH—osteoporosis	9.4e-05	0.00166	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—BMP2—osteoporosis	9.4e-05	0.00166	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—TNF—osteoporosis	9.38e-05	0.00166	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—LRP6—osteoporosis	9.3e-05	0.00165	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PTHLH—osteoporosis	9.24e-05	0.00164	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—FGB—osteoporosis	9.2e-05	0.00163	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CALCA—osteoporosis	9.16e-05	0.00162	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CALCA—osteoporosis	8.96e-05	0.00159	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PSMA2—osteoporosis	8.88e-05	0.00157	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PSMA5—osteoporosis	8.88e-05	0.00157	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—FDPS—osteoporosis	8.82e-05	0.00156	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PKM—osteoporosis	8.82e-05	0.00156	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—POMC—osteoporosis	8.48e-05	0.0015	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PGLS—osteoporosis	8.36e-05	0.00148	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GPD2—osteoporosis	8.36e-05	0.00148	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CALCA—osteoporosis	8.32e-05	0.00147	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—POMC—osteoporosis	8.3e-05	0.00147	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CALCA—osteoporosis	8.28e-05	0.00147	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	8.27e-05	0.00146	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CALCA—osteoporosis	8.14e-05	0.00144	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—POMC—osteoporosis	8.07e-05	0.00143	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TLN1—osteoporosis	8.03e-05	0.00142	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TLN1—osteoporosis	7.86e-05	0.00139	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ATIC—osteoporosis	7.64e-05	0.00135	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PNP—osteoporosis	7.64e-05	0.00135	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—KL—osteoporosis	7.52e-05	0.00133	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—POMC—osteoporosis	7.33e-05	0.0013	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—IL6R—osteoporosis	7.15e-05	0.00127	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—P4HB—osteoporosis	6.92e-05	0.00123	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—P4HB—osteoporosis	6.77e-05	0.0012	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PTH—osteoporosis	6.74e-05	0.00119	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—RAP1A—osteoporosis	6.62e-05	0.00117	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PTH—osteoporosis	6.59e-05	0.00117	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CNR2—osteoporosis	6.56e-05	0.00116	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—ADCY5—osteoporosis	6.52e-05	0.00115	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—OXCT1—osteoporosis	6.5e-05	0.00115	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CA2—osteoporosis	6.5e-05	0.00115	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—RAP1A—osteoporosis	6.48e-05	0.00115	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NFATC1—osteoporosis	6.46e-05	0.00114	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CNR2—osteoporosis	6.42e-05	0.00114	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—DKK1—osteoporosis	6.41e-05	0.00113	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—ADCY5—osteoporosis	6.37e-05	0.00113	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—MGLL—osteoporosis	6.33e-05	0.00112	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NFATC1—osteoporosis	6.32e-05	0.00112	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—DKK1—osteoporosis	6.27e-05	0.00111	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—WNT1—osteoporosis	6.17e-05	0.00109	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—WNT1—osteoporosis	6.04e-05	0.00107	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FGA—osteoporosis	6e-05	0.00106	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—ADCY5—osteoporosis	5.92e-05	0.00105	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—ADCY5—osteoporosis	5.89e-05	0.00104	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FGA—osteoporosis	5.87e-05	0.00104	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—ADCY5—osteoporosis	5.79e-05	0.00102	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—SPP1—osteoporosis	5.7e-05	0.00101	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PTHLH—osteoporosis	5.58e-05	0.000988	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—BMP2—osteoporosis	5.58e-05	0.000988	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FGB—osteoporosis	5.46e-05	0.000967	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PTHLH—osteoporosis	5.46e-05	0.000966	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—BMP2—osteoporosis	5.46e-05	0.000966	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—IDH2—osteoporosis	5.39e-05	0.000953	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FGB—osteoporosis	5.34e-05	0.000946	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PSMA5—osteoporosis	5.27e-05	0.000933	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PSMA2—osteoporosis	5.27e-05	0.000933	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PSMA5—osteoporosis	5.16e-05	0.000913	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PSMA2—osteoporosis	5.16e-05	0.000913	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IRS2—osteoporosis	5.15e-05	0.000912	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP27A1—osteoporosis	5.06e-05	0.000896	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—LEP—osteoporosis	5.04e-05	0.000892	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	4.97e-05	0.000879	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	4.96e-05	0.000877	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ACP5—osteoporosis	4.93e-05	0.000872	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CALCA—osteoporosis	4.91e-05	0.00087	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—ESR1—osteoporosis	4.81e-05	0.000852	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CALCA—osteoporosis	4.81e-05	0.000851	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—POMC—osteoporosis	4.79e-05	0.000848	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—POMC—osteoporosis	4.69e-05	0.00083	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	4.64e-05	0.000821	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	4.63e-05	0.000819	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—TPI1—osteoporosis	4.58e-05	0.00081	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IRS1—osteoporosis	4.5e-05	0.000796	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—KL—osteoporosis	4.46e-05	0.00079	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—KL—osteoporosis	4.36e-05	0.000773	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—POMC—osteoporosis	4.35e-05	0.00077	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—POMC—osteoporosis	4.33e-05	0.000767	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—P4HB—osteoporosis	4.31e-05	0.000762	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—POMC—osteoporosis	4.26e-05	0.000754	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—IL6R—osteoporosis	4.25e-05	0.000751	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GAPDH—osteoporosis	4.23e-05	0.000748	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IL6R—osteoporosis	4.23e-05	0.000748	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IGF1—osteoporosis	4.17e-05	0.000737	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—IL6R—osteoporosis	4.15e-05	0.000735	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—RAP1A—osteoporosis	4.12e-05	0.000728	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ADCY5—osteoporosis	3.5e-05	0.000619	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ADCY5—osteoporosis	3.42e-05	0.000605	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SPP1—osteoporosis	3.38e-05	0.000599	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ENO1—osteoporosis	3.33e-05	0.000589	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SPP1—osteoporosis	3.31e-05	0.000585	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PSMA2—osteoporosis	3.28e-05	0.00058	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PSMA5—osteoporosis	3.28e-05	0.00058	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—IL6—osteoporosis	3.19e-05	0.000564	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IRS2—osteoporosis	3.06e-05	0.000541	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—LEP—osteoporosis	2.99e-05	0.00053	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IRS2—osteoporosis	2.99e-05	0.000529	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—LEP—osteoporosis	2.93e-05	0.000518	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ESR1—osteoporosis	2.86e-05	0.000506	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ESR1—osteoporosis	2.8e-05	0.000495	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IRS1—osteoporosis	2.67e-05	0.000473	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP19A1—osteoporosis	2.66e-05	0.000471	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IRS1—osteoporosis	2.61e-05	0.000462	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—POMC—osteoporosis	2.57e-05	0.000455	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—POMC—osteoporosis	2.51e-05	0.000445	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IL6R—osteoporosis	2.51e-05	0.000444	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MYC—osteoporosis	2.5e-05	0.000443	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—TGFB1—osteoporosis	2.5e-05	0.000442	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IGF1—osteoporosis	2.47e-05	0.000438	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IL6R—osteoporosis	2.45e-05	0.000434	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IGF1—osteoporosis	2.42e-05	0.000428	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ADCY5—osteoporosis	2.17e-05	0.000385	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GPX1—osteoporosis	2.17e-05	0.000383	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—MTHFR—osteoporosis	2e-05	0.000354	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—IL6—osteoporosis	1.89e-05	0.000335	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IL6—osteoporosis	1.88e-05	0.000333	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—IL6—osteoporosis	1.85e-05	0.000327	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—POMC—osteoporosis	1.6e-05	0.000283	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MYC—osteoporosis	1.49e-05	0.000263	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TGFB1—osteoporosis	1.48e-05	0.000262	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MYC—osteoporosis	1.45e-05	0.000257	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TGFB1—osteoporosis	1.45e-05	0.000257	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IL6—osteoporosis	1.12e-05	0.000198	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IL6—osteoporosis	1.09e-05	0.000193	CbGpPWpGaD
